Medical Laboratory Personnel Shortage Relief Act Aims to Dent the Staffing Crisis
How the 2024 proposal will fare on Capitol Hill in 2025 remains to be seen, though
How the 2024 proposal will fare on Capitol Hill in 2025 remains to be seen, though
How clinical laboratory professionals can advocate for legislative and regulatory improvements
Joyce Gresko, partner at Alston & Bird, discusses the latest on PAMA and what will likely need to happen for SALSA to pass in 2024.
Comments on the FDA’s proposed rule to regulate LDTs as in vitro diagnostic devices reveal mixed reactions.
Genialis CEO and co-founder Rafael Rosengarten, PhD, discusses key 2023 AI developments and what they could mean for laboratories.
An overview of PAMA and key aspects lab compliance officers should be aware of to help ensure compliance.
On Oct. 28, the US Department of Health and Human Services served notice that it plans to repeal a controversial Trump rule.
From - Lab Compliance Advisor
While FDA oversight over new diagnostic tests is perfectly acceptable, what is objectionable is the…